Vietnam’s growing investment in diagnostic imaging is creating new opportunities for contrast media manufacturers as hospitals and diagnostic centres expand the use of CT, MRI, angiography and other advanced imaging technologies.
While dedicated Vietnam market studies exist, their publicly available summaries do not disclose reliable headline revenue figures. Based on Vietnam’s diagnostic imaging sector, regional market trends and global contrast media benchmarks, the Vietnam Contrast Media Market is estimated to be worth approximately US$45–65 million in 2025 and could reach US$65–90 million by 2030.
These figures should be considered an indicative market estimate rather than a published Vietnam-specific valuation.
Contrast media — also known as contrast agents — are pharmaceutical substances administered to patients to improve the visibility of organs, blood vessels and tissues during medical imaging procedures. They are essential to many modern diagnostic and interventional procedures, allowing clinicians to detect abnormalities and make more accurate diagnoses.
The market encompasses several major product categories:
- Iodinated contrast media
- Gadolinium-based contrast media
- Barium-based contrast media
- Microbubble contrast agents
- CT and X-ray imaging
- MRI imaging
- Contrast-enhanced ultrasound
- Interventional radiology
- Interventional cardiology
CT and X-ray imaging represent particularly important applications. Iodinated contrast agents are widely used during CT examinations and angiography to improve visualisation of blood vessels and internal organs, supporting the diagnosis of cardiovascular disease, cancer, neurological disorders and a wide range of other conditions.
MRI represents another important growth area. Gadolinium-based contrast agents enhance differences between normal and abnormal tissues and are widely used in neurological, musculoskeletal, cardiovascular and oncology imaging.
Vietnam-specific market research identifies increasing chronic disease prevalence, growing demand for advanced medical imaging and continued healthcare modernisation as important drivers of the country's contrast media market.
The growing burden of cancer and cardiovascular disease is particularly significant. Both require sophisticated diagnostic imaging throughout the patient pathway — from initial diagnosis and disease staging through treatment planning and follow-up — creating recurring demand for contrast-enhanced examinations.
Investment in imaging infrastructure is another important catalyst. As Vietnamese hospitals expand access to CT and MRI equipment, demand extends beyond scanners themselves to the pharmaceutical agents, injectors, consumables and software required to perform contrast-enhanced examinations.
This creates a wider commercial ecosystem encompassing contrast agents, contrast media injectors, syringes and consumables, imaging software, dose-management systems and associated clinical services.
Safety and innovation are also shaping the market. Manufacturers continue to develop contrast agents designed to improve diagnostic performance while reducing potential adverse effects. Non-ionic and low-osmolar iodinated agents are increasingly important in CT imaging, while research continues into improved gadolinium agents and next-generation alternatives for MRI.
Artificial intelligence could further influence the market. AI-enabled image reconstruction and enhancement technologies have the potential to improve image quality while helping clinicians optimise contrast doses. Combining advanced imaging equipment, AI and more sophisticated contrast protocols could enable healthcare providers to achieve higher-quality diagnostic information with increasingly personalised examinations.
Globally, contrast media represents a substantial healthcare market. IMARC Group estimates the global Contrast Media Market reached US$5.1 billion in 2025 and will grow to US$6.9 billion by 2034, driven by increasing diagnostic imaging volumes and rising prevalence of cardiovascular, neurological and oncological diseases.
Other market researchers expect faster expansion. Coherent Market Insights forecasts the global market to reach US$12.02 billion by 2033, with Asia-Pacific expected to be the fastest-growing regional market.
Vietnam is well positioned to participate in this regional expansion. Rising healthcare expenditure, increasing access to advanced imaging, development of private hospitals and diagnostic centres, and growing demand for earlier disease detection should continue to increase utilisation of contrast-enhanced imaging.
The opportunity extends beyond contrast media manufacturers. Suppliers of CT and MRI systems, contrast injectors, diagnostic imaging software, AI technologies, hospital equipment and radiology solutions all stand to benefit as Vietnam continues to modernise its diagnostic infrastructure.
For international medical imaging and pharmaceutical companies, Vietnam therefore represents a developing market with considerable long-term potential as advanced diagnostic imaging becomes more widely accessible across the country's healthcare system.